Infections and malignancies risks related to TNF-α-blocking agents in pediatric inflammatory bowel diseases

References

• Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321.
   PubMed Web of Science ®Google Scholar
• Bousvaros A, Sylvester F, Kugathasan S, et al. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:885–913.
   PubMed Web of Science ®Google Scholar
• Abramson O, Durant M, Mow W, et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr. 2010;157:233–9.e1.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519–525.
   PubMed Web of Science ®Google Scholar
• Castro M, Papadatou B, Baldassare M, et al. Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996–2003). Inflamm Bowel Dis. 2008;14:1246–1252.
   PubMed Web of Science ®Google Scholar
• Nuti F, Civitelli F, Cucchiara S. Long-term safety of immunomodulators in pediatric inflammatory diseases. Paediatr Drugs. 2014;16:343–352.
   PubMed Web of Science ®Google Scholar
• Peloquin JM, Goel G, Villablanca EJ, et al. Mechanisms of pediatric inflammatory bowel disease. Annu Rev Immunol. 2016;34:31–64.
   PubMed Web of Science ®Google Scholar
• Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52:31–37.
   PubMed Web of Science ®Google Scholar
• Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146:383–391.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468.
   PubMed Web of Science ®Google Scholar
• Krok KL, Lichtenstein GR. Nutrition in Crohn disease. Curr Opin Gastroenterol. 2003;19:148–153.
   PubMed Web of Science ®Google Scholar
• Tegtmeyer D, Seidl M, Gerner P, et al. Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm. Pediatr Allergy Immunol. 2017;28:412–429.
   PubMed Web of Science ®Google Scholar
• Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:990–1007.e3.
   PubMed Web of Science ®Google Scholar
• Uhlig HH, Schwerd T. From genes to mechanisms: the expanding spectrum of monogenic disorders associated with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:202–212.
   PubMed Web of Science ®Google Scholar
• Ardura MI, Toussi SS, Siegel JD, et al. NASPGHAN Clinical Report: surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-α inhibitors. J Pediatr Gastroenterol Nutr. 2016;63:130–155.
   PubMed Web of Science ®Google Scholar
• Andersen NN, Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J Gastroenterol. 2014;20:16014–16019.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-TNF therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(7):1293–1301..
   Web of Science ®Google Scholar
• Aloi M, D’Arcangelo G, Capponi M, et al. Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: efficacy of infliximab as a rescue therapy. Dig Liver Dis. 2015;47:455–459.
   PubMedGoogle Scholar
• Veereman-Wauters G, de Ridder L, Veres G, et al. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary. J Pediatr Gastroenterol Nutr. 2012;54:830–837.
   PubMed Web of Science ®Google Scholar
• Toussi SS, Pan N, Walters HM, et al. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-alpha inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57:1318–1330.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–1451.
   PubMed Web of Science ®Google Scholar
• Dziechciarz P, Horvath A, Kierkuś J. Efficacy and safety of adalimumab for paediatric Crohn’s disease: A systematic review. J Crohns Colitis. 2016;10:1237–1244.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524.
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Reinisch W, Panaccione R, et al. Lymphoma risk and overall safety profile of adalimumab in patients with Crohn’s disease with up to 6 years of follow-up in the Pyramid Registry. Am J Gastroenterol. 2018;113:872–882.
   PubMed Web of Science ®Google Scholar
• Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn’s disease: a population-based study. Inflamm Bowel Dis. 2011;17:2144–2152.
   PubMed Web of Science ®Google Scholar
• Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:946–953.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887–895.
   PubMed Web of Science ®Google Scholar
• D’Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut. 2007;56:725–732.
   PubMed Web of Science ®Google Scholar
• Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69:400–408.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–1452.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti Tumor Necrosis Factor and immunomodulator therapy for the treatment of Crohn’s disease: A meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–881.
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945–965.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Vacek PM, O’Neill P, et al. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res. 2009;69:7004–7012.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152:1901–1914.e3.
   Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.
   PubMed Web of Science ®Google Scholar
• Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis. 2012;18:838–843.
   PubMed Web of Science ®Google Scholar
• Aardoom MA, Joosse ME, ACH DV, et al. Malignancy and mortality in pediatric-onset inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2018;24:732–741.
   PubMed Web of Science ®Google Scholar
• Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010;4:511–522.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2927–2936.
   PubMed Web of Science ®Google Scholar
• Selvaraj SA, Chairez E, Wilson LM, et al. Use of case reports and the adverse event reporting system in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma. Syst Rev. 2013;2:53.
   PubMedGoogle Scholar
• de Ridder L, Turner D, Wilson DC, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. Inflamm Bowel Dis. 2014;20:291–300.
   PubMed Web of Science ®Google Scholar
• Ross S, Rajwal SK, Sugarman I, et al. Epstein-Barr virus-associated lymphoproliferative disorder in Crohn disease treated with azathioprine. J Pediatr Gastroenterol Nutr. 2010;51:229–231.
   PubMed Web of Science ®Google Scholar
• Gidrewicz D, Lehman D, Rabizadeh S, et al. Primary EBV infection resulting in lymphoproliferative disease in a teenager with Crohn disease. J Pediatr Gastroenterol Nutr. 2011;52:103–105.
   PubMed Web of Science ®Google Scholar
• Fitzgerald MP, Armstrong L, Hague R, et al. A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn’s disease patient on azathioprine, successfully treated with rituximab. J Crohns Colitis. 2013;7:314–317.
   PubMed Web of Science ®Google Scholar